

Accepted Manuscript


Title: Morphologic Dysplasia in Myelodysplastic Syndromes:
How accurate are morphologists?

Author: John M. Bennett

PII: S0145-2126(18)30135-8
DOI: <https://doi.org/10.1016/j.leukres.2018.06.012>
Reference: LR 5983

To appear in: *Leukemia Research*

Received date: 29-5-2018



Please cite this article as: Bennett JM, Morphologic Dysplasia in Myelodysplastic Syndromes: How accurate are morphologists?, *Leukemia Research* (2018), <https://doi.org/10.1016/j.leukres.2018.06.012>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Morphologic Dysplasia in Myelodysplastic Syndromes: How accurate are morphologists?

John M. Bennett, M.D.

University of Rochester Medical Center, Rochester, New York, USA

Corresponding Author:

John M. Bennett, MD

Professor of Medicine, Pathology and Laboratory Medicine, Departments of Pathology and Medicine; James P. Wilmot Cancer Institute

University of Rochester, New York 14642, USA

Tel: 585-275-4915

Fax: 585-276-2390

Email: john_bennett@urmc.rochester.edu

NOTE: To accompany: LR-D-18-00068 and LR-D-18-00104

Key words: Myelodysplastic syndrome; dyserythropoiesis; dysgranulopoiesis; dysmegakaryocytopoiesis

Word count: 1,073

In the absence of an increased % of blasts (5-19%) and accepted cytogenetic findings [(-7, del(7),del(5q), isochromosome 17q or l(17p), -13 or del(13q), (-11), and rarer losses and translocations]¹ a diagnosis of Myelodysplastic Syndromes (MDS) can still be made in the presence of cytopenias and morphologic dysplasia (“abnormal growth or development of cells”)² that persists for several months.

Traditionally dysplasia can be recognized in one or more of the following cell lines: Erythroid, Granulocytic, and Megakaryocytic. Dysplastic aberrations in monocytic, eosinophilic or basophilic cells is problematic and are not considered currently in MDS classification schemas.

In this current issue of Leukemia Research Sasada and co-authors have carried out an extensive morphologic investigation, utilizing well trained laboratory technologists to study many of the dysplastic features of granulocytes described in the WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues.³ Their results were disappointing in that concordance as measured by the Kappa statistic was poor.

Download English Version:

<https://daneshyari.com/en/article/8453274>

Download Persian Version:

<https://daneshyari.com/article/8453274>

[Daneshyari.com](https://daneshyari.com)